NASDAQ:ILMN Illumina (ILMN) Stock Price, News & Analysis $120.43 +3.13 (+2.67%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$117.77▼$123.8750-Day Range$101.05▼$125.2352-Week Range$89.00▼$195.64Volume1.47 million shsAverage Volume2.13 million shsMarket Capitalization$19.18 billionP/E RatioN/ADividend YieldN/APrice Target$158.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Illumina alerts: Email Address Illumina MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside31.7% Upside$158.57 Price TargetShort InterestHealthy3.00% of Shares Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment1.04Based on 19 Articles This WeekInsider TradingN/AProj. Earnings Growth120.29%From $1.38 to $3.04 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.87 out of 5 starsMedical Sector28th out of 936 stocksAnalytical Instruments Industry2nd out of 27 stocks 4.2 Analyst's Opinion Consensus RatingIllumina has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 9 buy ratings, 10 hold ratings, and 2 sell ratings.Amount of Analyst CoverageIllumina has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Illumina's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.00% of the outstanding shares of Illumina have been sold short.Short Interest Ratio / Days to CoverIllumina has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Illumina has recently decreased by 4.78%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldIllumina does not currently pay a dividend.Dividend GrowthIllumina does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIllumina has received a 61.69% net impact score from Upright. Illumina seems to create the most significant positive value in categories "Taxes", "Jobs", and "Physical diseases". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Laboratory reagents", "DNA sequencers", and "Laboratory reagents for cells" products. See details.Environmental SustainabilityThe Environmental Impact score for Illumina is -1.11. Previous Next 3.4 News and Social Media Coverage News SentimentIllumina has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Illumina this week, compared to 14 articles on an average week.Search InterestOnly 25 people have searched for ILMN on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows13 people have added Illumina to their MarketBeat watchlist in the last 30 days. This is an increase of 86% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Illumina insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.17% of the stock of Illumina is held by insiders.Percentage Held by Institutions89.42% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Illumina's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Illumina are expected to grow by 120.29% in the coming year, from $1.38 to $3.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Illumina is -14.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Illumina is -14.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIllumina has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Illumina's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Illumina Stock (NASDAQ:ILMN)Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.Read More ILMN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ILMN Stock News HeadlinesJuly 16, 2024 | marketbeat.comStrategic Buy Lights Up This Biotech Stock: Time to Invest?Life sciences company Illumina Inc. NASDAQ: ILMN stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. This comes after its divestiture and spin-off of GRAIL, LLC NASDAQ: GRAL on June 24, 2024.July 16, 2024 | marketbeat.comStrategic Buy Lights Up This Biotech Stock: Time to Invest?Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences.July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 24 at 1:59 PM | msn.comHere’s Why You Should Add Illumina (ILMN) to Your PortfolioJuly 24 at 3:56 AM | sg.finance.yahoo.comILMN Jul 2024 130.000 callJuly 23 at 5:54 PM | marketwatch.comIllumina Inc. stock outperforms competitors despite losses on the dayJuly 22, 2024 | seekingalpha.comIllumina: Strengthening Competitive Position, Relevance And A Very Compelling ValuationJuly 22, 2024 | americanbankingnews.comBrokers Offer Predictions for Illumina, Inc.'s Q3 2024 Earnings (NASDAQ:ILMN)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 21, 2024 | sg.finance.yahoo.comILLUMINA (1ILMN.MI) interactive stock chart – Yahoo FinanceJuly 21, 2024 | investorplace.com3 Precision Medicine Stocks Tailoring TreatmentsJuly 19, 2024 | benzinga.com$1000 Invested In Illumina 20 Years Ago Would Be Worth This Much TodayJuly 19, 2024 | finance.yahoo.comShould You Consider Adding Illumina (ILMN) to Your Portfolio?July 18, 2024 | prnewswire.comIllumina to Present Upcoming Strategy UpdateJuly 11, 2024 | prnewswire.comIllumina to Announce Second Quarter 2024 Financial Results on Tuesday, August 6, 2024July 9, 2024 | prnewswire.comIllumina acquires Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer baseJuly 5, 2024 | investorplace.com3 Biotech Stocks Turning DNA Dreams Into DollarsJune 28, 2024 | investopedia.comIllumina Takes a $1.47 Billion Charge Related to Its Spinoff of GRAILSee More Headlines Receive ILMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:ILMN CUSIP45232710 CIK1110803 Webwww.illumina.com Phone(858) 202-4500Fax858-202-4766Employees9,300Year Founded1998Price Target and Rating Average Stock Price Target$158.57 High Stock Price Target$242.00 Low Stock Price Target$100.00 Potential Upside/Downside+31.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)($8.15) Trailing P/E RatioN/A Forward P/E Ratio87.27 P/E GrowthN/ANet Income$-1,161,000,000.00 Net Margins-28.71% Pretax Margin-25.55% Return on Equity2.31% Return on Assets1.31% Debt Debt-to-Equity Ratio0.26 Current Ratio1.75 Quick Ratio1.36 Sales & Book Value Annual Sales$4.50 billion Price / Sales4.26 Cash Flow$3.71 per share Price / Cash Flow32.46 Book Value$36.18 per share Price / Book3.33Miscellaneous Outstanding Shares159,300,000Free Float159,029,000Market Cap$19.18 billion OptionableOptionable Beta1.15 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Jacob Thaysen Ph.D. (Age 49)CEO & Director Comp: $796.63kMs. Carissa L. Rollins (Age 54)Chief Information Officer Comp: $693.52kMr. Charles E. Dadswell Esq. (Age 65)Senior VP & General Counsel Comp: $1.03MDr. Joydeep Goswami M.B.A. (Age 53)Ph.D., Advisor Comp: $843.55kStephanie CamposPresidentMr. Ankur Dhingra (Age 48)Chief Financial Officer Mr. Kevin Carl Pegels (Age 56)Chief of Global Operations Mr. Scott Ericksen (Age 51)VP & Chief Accounting Officer Dr. Steven Barnard Ph.D.Chief Technology OfficerMs. Sallilyn SchwartzVice President of Investor RelationsMore ExecutivesKey CompetitorsRevvityNYSE:PKIBerkeley LightsNASDAQ:BLIAgilent TechnologiesNYSE:AMettler-Toledo InternationalNYSE:MTDWatersNYSE:WATView All CompetitorsInsiders & InstitutionsState of Michigan Retirement SystemSold 5,130 shares on 7/26/2024Ownership: 0.024%Legato Capital Management LLCBought 2,100 shares on 7/26/2024Ownership: 0.009%RiverPark Advisors LLCBought 1,166 shares on 7/26/2024Ownership: 0.005%Riverpark Capital Management LLCBought 1,586 shares on 7/26/2024Ownership: 0.005%IMA Advisory Services Inc.Bought 4,524 shares on 7/26/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions Should I Buy Illumina Stock? ILMN Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Illumina, Inc.: Illumina's stock price is currently at $109.22, potentially offering a good entry point for investors looking to buy at a lower price. The company operates through Core Illumina and GRAIL segments, providing diversified revenue streams and exposure to different markets. Illumina reported positive return on equity of 2.31% in the latest earnings results, indicating efficient use of shareholder funds. Despite a negative net margin, Illumina's revenue for the quarter was $1.08 billion, surpassing analyst expectations and demonstrating strong sales performance. With a market cap of $17.40 billion, Illumina is a well-established player in the genetic and genomic analysis industry, offering stability and potential for growth. Cons Investors should be bearish about investing in Illumina, Inc. for these reasons: Analysts have issued mixed ratings on Illumina's stock, with two sell ratings, eleven hold ratings, and nine buy ratings, indicating uncertainty and differing opinions about the company's future performance. The company's PE ratio of -13.40 may raise concerns among investors, as a negative PE ratio could suggest potential overvaluation or financial challenges. Despite beating earnings estimates, Illumina's EPS of $0.09 for the quarter was only a slight improvement from the prior year, raising questions about the company's ability to significantly grow its profitability. Evercore ISI lowered their price target on Illumina from $195.00 to $175.00, signaling a bearish outlook on the stock's potential future performance. Barclays increased their target price on Illumina from $85.00 to $100.00 but gave the stock an "underweight" rating, suggesting concerns about the stock's valuation and growth prospects. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com. ILMN Stock Analysis - Frequently Asked Questions How have ILMN shares performed this year? Illumina's stock was trading at $139.24 at the beginning of 2024. Since then, ILMN shares have decreased by 13.5% and is now trading at $120.43. View the best growth stocks for 2024 here. How were Illumina's earnings last quarter? Illumina, Inc. (NASDAQ:ILMN) issued its quarterly earnings data on Thursday, May, 2nd. The life sciences company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. The company's quarterly revenue was down 1.0% compared to the same quarter last year. Read the conference call transcript. What is Francis deSouza's approval rating as Illumina's CEO? 496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Does Illumina have any subsidiaries? Illumina subsidiaries include Grail, Enancio, BlueBee, Edico Genome, Conexio Genomics, GenoLogics, NextBio, and others. Who are Illumina's major shareholders? Top institutional shareholders of Illumina include Baillie Gifford & Co. (3.52%), Bank of New York Mellon Corp (1.91%), Swedbank AB (0.36%) and Chevy Chase Trust Holdings LLC (0.28%). Insiders that own company stock include Susan H Tousi, Jacob Thaysen, Aimee L Hoyt, Charles Dadswell, Phillip G Febbo and Alexander Aravanis. View institutional ownership trends. How do I buy shares of Illumina? Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Illumina own? Based on aggregate information from My MarketBeat watchlists, some other companies that Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL) and Salesforce (CRM). This page (NASDAQ:ILMN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Illumina, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Illumina With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
